Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033

Monoclonal Antibodies (mAbs) Market 2024 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Infectious Diseases, Hematological Disease, Other Applications), By End-Users (Hospitals, Specialty Centers, Other End-Users), And By Region, Opportunities And Strategies – Global Forecast To 2033

Name: Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033

Starting Price : $5000.00 $3500.00 | Pages : 279 | Published : April 2024 | | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

Monoclonal Antibodies (mAbs)Market Definition

Monoclonal antibodies (mAbs) are laboratory-produced antibodies that specifically bind to target molecules with high affinity, avidity and specificity. This binding results in inhibition of the target molecule’s biological function by blocking its interaction with other receptor proteins or directing its destruction and elimination.

The monoclonal antibodies (mAbs) market consists of sales by entities (organizations, sole traders and partnerships), that produce monoclonal antibodies used to treat various medical conditions including cancer, inflammatory and autoimmune diseases.

Book your 30 minutes free consultation with our research experts

Monoclonal Antibodies (mAbs)Market Size

The global monoclonal antibodies (mAbs) market reached a value of nearly $209,853.6 million in 2023, having grown at a compound annual growth rate (CAGR) of 12.8% since 2018. The market is expected to grow from $209,853.6 million in 2023 to $ 375,412.3 million in 2028 at a rate of 12.3%. The market is then expected to grow at a CAGR of 12.4% from 2028 and reach $673,130.7 million in 2033.

Growth in the historic period resulted from the strong economic growth in emerging markets, increasing focus on personalized medicine, increase in R&D expenditure and government initiatives. Factors that negatively affected growth in the historic period were pricing pressures from regulators.

Going forward, increasing chronic diseases, rise in healthcare expenditure, increasing prevalence of cancer and increasing aging population will drive the growth. Factor that could hinder the growth of the monoclonal antibodies (mAbs) market in the future include high cost in development of monoclonal antibodies, stringent regulatory guidelines and usage of surrogate endpoints in clinical trials.

Monoclonal Antibodies (mAbs) Market Drivers

The key drivers of the monoclonal antibodies (mabs) market include:

Increasing Chronic Diseases

The increasing number of chronic diseases is expected to contribute to the growth of the monoclonal antibodies MAbs market going forward. Chronic diseases often require long-term medication management and patients with these conditions can benefit greatly from personalized treatment approaches. Monoclonal antibodies provide a customized way to target and fight against specific elements of disease pathology. According to the Centres for Disease Control and Prevention, a US-based national public health agency, chronic diseases will be among the most prevalent diseases, with 6 out of 10 adults suffering from at least one chronic disease in the USA. According to the National Library of Medicine, a US-based agency, the number of individuals in the US aged 50 and older who have at least one chronic condition will increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. The increasing number of chronic diseases is expected to generate high demand for the mAbs market.

Monoclonal Antibodies (mAbs) Market Restraints

The key restraints on the monoclonal antibodies (mabs) market include:

Stringent Regulatory Guidelines

Stringent regulations related to safety, efficacy and quality are projected to act as a major challenge for players operating in the monoclonal antibodies market. All medicines and treatments go through stringent testing in the lab (pre-clinical research) and in small groups of patients (clinical research). The European Medicines Agency (EMA) and The United States Food and Drug Administration (FDA) are the two main bodies regulating these novel therapies while getting them to market. Health Canada uses mAb specific guidelines from EMA or USFDA when necessary. The SAHPRA (South African Health Products Authority) biosimilar guideline has an annex on mAbs which focuses on non-clinical and clinical aspects. The Russian Federation has issued general product registration guideline/s with very brief information about mAbs. Since it is a time-consuming process, it is considered as one of the major hindering factors for this market.

Monoclonal Antibodies (mAbs) Market Trends

Major trends shaping the monoclonal antibodies (mabs) market include:

Investment in Targeted and Combination Therapy

Companies in the monoclonal antibodies (mAbs) market are investing in targeted and combination therapy, which has been proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, in September 2022, the European Union (EU) granted approval for AstraZeneca's Evusheld (comprising tixagevimab and cilgavimab, previously known as AZD7442). This long-acting antibody combination was authorized for treating COVID-19 in adults and adolescents (aged 12 years and older, weighing at least 40 kg) who do not need supplemental oxygen and face an elevated risk of developing severe COVID-19. Also, in January 2020, European Commission has granted conditional marketing authorization for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.

Integration of Artificial Intelligence for Accelerated Innovation

Companies in the monoclonal antibodies (mAbs) market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI solutions can successfully identify disease patterns in large datasets and this information can be used to determine the optimal drug formulations for treating various diseases. For instance, in October 2023, BigHat Biosciences a US- based a protein therapeutics company is leveraging artificial intelligence (AI) and machine learning (ML) to drive innovation in the development of monoclonal antibodies (mAbs). The company has built a platform that integrates the best of AI/ML and life sciences wet lab to accelerate the development of antibody fragments. By aligning to areas with high-quality assays predictive of clinical efficacy and safety, Biosciences aims to optimize its molecules to those measurements, enabling the rapid iteration of its AI/ML methods. The company's focus is on areas with well-understood biology, especially high-resolution and high-quality assays and it is exploring new, green fields of molecular space made possible by its AI/ML integrated platform.

Opportunities And Recommendations In The Monoclonal Antibodies (mAbs) Market

Opportunities – The top opportunities in the monoclonal antibodies (mAbs) market segmented by source will arise in the human segment, which will gain $80,220.5 million of global annual sales by 2028. The top opportunities in the monoclonal antibodies (mAbs) market segmented by application will arise in the anti-cancer segment, which will gain $65,857.2 million of global annual sales by 2028. The top opportunities in the monoclonal antibodies (mAbs) market segmented by end-users will arise in the hospitals segment, which will gain $108,459.7 million of global annual sales by 2028. The monoclonal antibodies (mAbs) market size will gain the most in USA at $67,883.9 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the monoclonal antibodies (mAbs) companies to focus on advancing targeted and combination therapies for market growth, focus on driving market growth through product innovation, focus on cancer biologics R&D, focus on revolutionizing research with AI integration, focus on human and humanized segments for growth, expand in emerging markets, continue to focus on developed markets, focus on strategic collaborations, focus on diversifying distribution channels, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on strategic promotion, focus on immunological and anti-cancer segments and focus on specialty centers and hospitals for strategic growth.

Monoclonal Antibodies (mAbs) Market Segmentation

The monoclonal antibodies (mabs) market is segmented by source, by application and by end-users.

By Source –
The monoclonal antibodies (mabs) market is segmented by source into:

a) Murine
b) Chimeric
c) Humanized
d) Human

The human market was the largest segment of the monoclonal antibodies (mAbs) market segmented by source, accounting for 43.2% or $90,590.6 million of the total in 2023. Going forward, the humanized segment is expected to be the fastest growing segment in the monoclonal antibodies (mAbs) market segmented by source, at a CAGR of 14.2% during 2023-2028.

By Application –
The monoclonal antibodies (mabs) market is segmented by application into:

a) Anti-Cancer
b) Immunological
c) Infectious Diseases
d) Hematological Disease
d) Other Applications

The anti-cancer market was the largest segment of the monoclonal antibodies (mAbs) market segmented by application, accounting for 38.9% or $81,664.8 million of the total in 2023. Going forward, the immunological segment is expected to be the fastest growing segment in the monoclonal antibodies (mAbs) market segmented by application, at a CAGR of 13.4% during 2023-2028.

By End Users –
The monoclonal antibodies (mabs) market is segmented by end users into:

a) Hospitals
b) Specialty Centers
c) Other End-Users

The hospitals market was the largest segment of the relays market segmented by end-users, accounting for 65.4% or $137,333.3 million of the total in 2023. Going forward, the specialty centers segment is expected to be the fastest growing segment in the relays market segmented by end-users, at a CAGR of 13.0% during 2023-2028.

By Geography - The monoclonal antibodies (mabs) market is segmented by geography into:

• China
• India
• Japan
• Australia
• Indonesia
• South Korea

• USA

• Brazil

• France
• Germany
• UK

• Russia

North America was the largest region in the monoclonal antibodies (mAbs) market, accounting for 45.8% or $96,118.7 million of the total in 2023. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the monoclonal antibodies (mAbs) market will be Asia Pacific and Western Europe where growth will be at CAGRs of 13.6% and 12.9% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 12.5% and 9.20% respectively.

Monoclonal Antibodies (Mabs) Market Competitive Landscape

Major Competitors are:

Johnson & Johnson Inc.

Merck & Co., Inc.

F. Hoffman-La Roche Ltd.

Bristol Myers Squibb

GlaxoSmithKline plc

Other Competitors Include:

Eli Lilly And Company

Pfizer Inc

Amgen Inc

Novartis AG

Eisai Co., Ltd

Biocon Limited

Dr. Reddy's Laboratories

Sun Pharmaceutical Industries Ltd

BeiGene, Ltd.

Shanghai Junshi Biosciences Co., Ltd

Innovent Biologics, Inc

Chugai Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Mitsubishi Tanabe Pharma Corporation

Celltrion, Inc.

Samsung Biologics Co., Ltd.

LG Chem Life Sciences

CSL Limited

Cochlear Limited

ResMed Inc.

Sino Biological

WuXi Biologics

3SBio Inc.

Shanghai Henlius Biotech, Inc.

CStone Pharmaceuticals

Sanofi S.A.

AstraZeneca

Merck KGaA

Bayer AG

EPIVAX, Inc.

Genentech

Boehringer Ingelheim Grifols

Almirall

BioInvent

Alligator Bioscience

Dompe Farmaceutici

BIOCAD

Sistema-Biotech

Nanolek

Mabion

Polpharma Biologics

Bioceros

Eurofarma

Hypermarcas

Biolab Farmacêutica

Laboratorios Richmond

andes Biotechnologies

Tecnoquimicas

Labinca

Libbs Farmaceutica

Hikma Pharmaceuticals

Neopharm

BBI Solutions

APC Pharma

EPICIO

Medical Union Pharmaceuticals

South Egypt Drug Industries Co. Pharmaceutical

Vacsera Pharma

Aspen Pharmacare

Amoun Pharmaceuticals CO Ltd.

54gene

Baxter International

Altis Biologics

Cipla Medpro South Africa

EPIVAX, Inc.

Genentech

1 Executive Summary

1.1 Monoclonal Antibodies (mAbs) – Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition

6.2 Summary

6.3 Monoclonal Antibodies (mAbs) Market Definition And Segmentations

6.4 Market Segmentation By Source

6.4.1 Murine

6.4.2 Chimeric

6.4.3 Humanized

6.4.4 Human

6.5 Market Segmentation By Application

6.5.1 Anti-Cancer

6.5.2 Immunological

6.5.3 Infectious Disease

6.5.4 Hematological Disease

6.5.5 Other Applications

6.6 Market Segmentation By End-Users

6.6.1 Hospitals

6.6.2 Specialty Centers

6.6.3 Other End-Users

7 Major Market Trends

7.1 Investment in Targeted and Combination Therapy

7.2 Strategic Partnerships And Collaborations Among Market Players To Drive Innovation and Expansion In The Market

7.3 R&D Investments Revolutionizing Treatment

7.4 Integration of Artificial Intelligence for Accelerated Innovation

7.5 Product Innovation In Novel Therapies and Biosimilars Expands Treatment Options

8 Monoclonal Antibodies (mAbs) Market – Macro-Economic Scenario

8.1 COVID-19 Impact On The Monoclonal Antibodies (mAbs) Market

8.2 Impact Of The War In Ukraine On The Monoclonal Antibodies (mAbs) Market

8.3 Impact Of High Inflation On The Monoclonal Antibodies (mAbs) Market

9 Global Market Size and Growth

9.1 Market Size

9.2 Historic Market Growth, 2018 – 2023, Value ($ Million)

9.2.1 Market Drivers 2018 – 2023

9.2.2 Market Restraints 2018 – 2023

9.3 Forecast Market Growth, 2023 – 2028, 2033F Value ($ Million)

9.3.1 Market Drivers 2023 – 2028

9.3.2 Market Restraints 2023 – 2028

10 Global Monoclonal Antibodies (mAbs) Market Segmentation

10.1 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

10.2 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

10.3 Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

11 Monoclonal Antibodies (mAbs) Market, Regional and Country Analysis

11.1 Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

11.2 Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12 Asia-Pacific Market

12.1 Summary

12.1.1 Market Overview

12.1.2 Region Information

12.1.3 Market Information

12.1.4 Background Information

12.1.5 Government Initiatives

12.1.6 Regulations

12.1.7 Regulatory Bodies

12.1.8 Major Associations

12.1.9 Taxes Levied

12.1.10 Corporate Tax Structure

12.1.11 Investments

12.1.12 Major Companies

12.2 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.3 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.4 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.5 Asia-Pacific Monoclonal Antibodies (mAbs) Market: Country Analysis

12.6 China Market

12.7 Summary

12.7.1 Market Overview

12.7.2 Country Information

12.7.3 Market Information

12.7.4 Background Information

12.7.5 Government Initiatives

12.7.6 Regulations

12.7.7 Regulatory Bodies

12.7.8 Major Associations

12.7.9 Taxes Levied

12.7.10 Corporate Tax Structure

12.7.11 Investments

12.7.12 Major Companies

12.8 China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.9 China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.1 China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.11 India Market

12.12 India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.13 India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.14 India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.15 Japan Market

12.16 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.17 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.18 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.19 Australia Market

12.2 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.21 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.22 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.23 Indonesia Market

12.24 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.25 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.26 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.27 South Korea Market

12.28 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.29 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

12.3 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13 Western Europe Market

13.1 Summary

13.1.1 Market Overview

13.1.2 Region Information

13.1.3 Market Information

13.1.4 Background Information

13.1.5 Government Initiatives

13.1.6 Regulations

13.1.7 Regulatory Bodies

13.1.8 Major Associations

13.1.9 Taxes Levied

13.1.10 Corporate tax structure

13.1.11 Investments

13.1.12 Major Companies

13.2 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.3 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.4 Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.5 Western Europe Monoclonal Antibodies (mAbs) Market: Country Analysis

13.6 UK Market

13.7 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.8 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.9 UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.1 Germany Market

13.11 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.12 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.13 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.14 France Market

13.15 France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.16 France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

13.17 France Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

14 Eastern Europe Market

14.1 Summary

14.1.1 Market Overview

14.1.2 Region Information

14.1.3 Market Information

14.1.4 Background Information

14.1.5 Government Initiatives

14.1.6 Regulations

14.1.7 Regulatory Bodies

14.1.8 Major Associations

14.1.9 Taxes Levied

14.1.10 Corporate Tax Structure

14.1.11 Investments

14.1.12 Major Companies

14.2 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

14.3 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

14.4 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

14.5 Eastern Europe Monoclonal Antibodies (mAbs) Market: Country Analysis

14.6 Russia Market

14.7 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

14.8 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

14.9 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

15 North America Market

15.1 Summary

15.1.1 Market Overview

15.1.2 Region Information

15.1.3 Market Information

15.1.4 Background Information

15.1.5 Government Initiatives

15.1.6 Regulations

15.1.7 Regulatory Bodies

15.1.8 Major Associations

15.1.9 Taxes Levied

15.1.10 Corporate Tax Structure

15.1.11 Investments

15.1.12 Major Companies

15.2 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

15.3 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

15.4 North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

15.5 North America Monoclonal Antibodies (mAbs) Market: Country Analysis

15.6 USA Market

15.7 Summary

15.7.1 Market Overview

15.7.2 Country Information

15.7.3 Market Information

15.7.4 Background Information

15.7.5 Government Initiatives

15.7.6 Regulations

15.7.7 Regulatory Bodies

15.7.8 Major Associations

15.7.9 Taxes Levied

15.7.10 Corporate Tax Structure

15.7.11 Investments

15.7.12 Major Companies

15.8 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

15.9 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

15.1 USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

16 South America Market

16.1 Summary

16.1.1 Market Overview

16.1.2 Region Information

16.1.3 Market Information

16.1.4 Background Information

16.1.5 Government Initiatives

16.1.6 Regulations

16.1.7 Regulatory Bodies

16.1.8 Major Associations

16.1.9 Taxes Levied

16.1.10 Corporate Tax Structure

16.1.11 Investments

16.1.12 Major Companies

16.2 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

16.3 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

16.4 South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

16.5 South America Monoclonal Antibodies (mAbs) Market: Country Analysis

16.6 Brazil Market

16.7 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

16.8 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

16.9 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

17 Middle East Market

17.1 Summary

17.1.1 Market Overview

17.1.2 Region Information

17.1.3 Market Information

17.1.4 Background Information

17.1.5 Government Initiatives

17.1.6 Regulations

17.1.7 Regulatory Bodies

17.1.8 Major Associations

17.1.9 Taxes Levied

17.1.10 Corporate Tax Structure

17.1.11 Investments

17.1.12 Major Companies

17.2 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

17.3 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

17.4 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

18 Africa Market

18.1 Summary

18.1.1 Market Overview

18.1.2 Region Information

18.1.3 Market Information

18.1.4 Background Information

18.1.5 Government Initiatives

18.1.6 Regulations

18.1.7 Regulatory Bodies

18.1.8 Major Associations

18.1.9 Taxes Levied

18.1.10 Corporate Tax Structure

18.1.11 Investment

18.1.12 Major Companies

18.2 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

18.3 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

18.4 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)

19 Competitive Landscape And Company Profiles

19.1 Company Profiles

19.2 Johnson & Johnson

19.2.1 Company Overview

19.2.2 Products And Services

19.2.3 Business Strategy

nal overview

19.3 Merck & Co., Inc.

19.3.1 Company Overview

19.3.2 Products And Services

19.3.3 Business Strategy

19.3.4 Financial Overview

19.4 F. Hoffman-La Roche Ltd.

19.4.1 Company Overview

19.4.2 Products And Services

19.4.3 Business Strategy

19.4.4 Financial Overview

19.5 Bristol Myers Squibb

19.5.1 Company Overview

19.5.2 Products And Services

19.5.3 Business Strategy

19.5.4 Financial Overview

19.6 GlaxoSmithKline plc

19.6.1 Company Overview

19.6.2 Products And Services

19.6.3 Business Strategy

19.6.4 Financial performance

20 Key Mergers And Acquisitions

20.1 Syngene Acquired Stelis Biopharma

20.2 Merck Acquired Prometheus Biosciences

20.3 Biocon Biologics Acquired Viatris Inc

20.4 Incyte Acquired Villaris Therapeutics

20.5 FUJIFILM Corporation Acquired Atara Biotherapeutics

20.6 Exelixis Inc. Acquired Gamamabs Pharma SA’s AMHR2 Antibody Technology

20.7 Sanofi Acquired Kymab Group Ltd.

20.8 Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.

20.9 Servier Acquired Symphogen A/S

20.1 Gilead Sciences Acquired Forty Seven

20.11 True North Acquired Stake In Biocon Biologics

21 Pipeline Analysis

22 Opportunities And Strategies

22.1 Global Monoclonal Antibodies (mAbs) Market In 2028 – Countries Offering Most New Opportunities

22.2 Global Monoclonal Antibodies (mAbs) Market In 2028 – Segments Offering Most New Opportunities

22.3 Global Monoclonal Antibodies (mAbs) Market In 2028 – Growth Strategies

22.3.1 Market Trend Based Strategies

22.3.2 Competitor Strategies

23 Monoclonal Antibodies Market, Conclusions And Recommendations

23.1 Conclusions

23.2 Recommendations

23.2.1 Product

23.2.2 Place

23.2.3 Price

23.2.4 Promotion

23.2.5 People

24 Appendix

24.1 Geographies Covered

24.2 Market Data Sources

24.3 Research Methodology

24.4 Currencies

24.5 The Business Research Company

24.6 Copyright and Disclaimer

List Of Tables

Table 1: Global Monoclonal Antibodies (mAbs) Market, Historic, 2018 – 2023, $ Million

Table 2: Global Monoclonal Antibodies (mAbs) Market, Forecast, 2023 – 2028, 2033F, $ Million

Table 3: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 4: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 5: Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 6: Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 7: Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 8: Asia-Pacific GDP Per Capita, By Country, 2018-2023, $

Table 9: Asia-Pacific Population, By Country, 2018-2028, Millions

Table 10: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 11: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 12: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 13: China GDP Per Capita, 2018-2023, $

Table 14: China Population, 2018-2028, Millions

Table 15: China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 16: China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 17: China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 18: India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 19: India Monoclonal antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 20: India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 21: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 22: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 23: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 24: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 25: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 26: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 27: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 28: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 29: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 30: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 31: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 32: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 33: Western Europe GDP Per Capita, By Country, 2018-2023, $

Table 34: Western Europe Population, By Country, 2018-2028, Millions

Table 35: Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 36: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 37: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 38: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 39: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 40: UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 41: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 42: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 43: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 44: France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 45: France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 46: France Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 47: Eastern Europe GDP Per Capita, By Country, 2018-2023, $

Table 48: Eastern Europe Population, By Country, 2018-2028, Millions

Table 49: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 50: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 51: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 52: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 53: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 54: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 55: North America GDP Per Capita, By Country, 2018-2023, $

Table 56: North America Population, By Country, 2018-2028, Millions

Table 57: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 58: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 59: North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 60: USA GDP Per Capita, 2018-2023, $

Table 61: USA Population, 2018-2028, Millions

Table 62: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 63: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 64: USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 65: South America GDP Per Capita, By Country, 2018-2023, $

Table 66: South America Population, By Country, 2018-2028, Millions

Table 67: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 68: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 69: South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 70: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 71: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 72: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 73: Middle East GDP Per Capita, By Country, 2018-2023, $

Table 74: Middle East Population, By Country, 2018-2028, Millions

Table 75: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 76: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 77: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 78: Africa GDP Per Capita, By Country, 2018-2023, $

Table 79: Africa Population, By Country, 2018-2028, Millions

Table 80: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 81: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 82: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Table 83: Global Monoclonal Antibodies (mAbs) Market, Key Competitor Estimated Market Shares, 2022, Percentage (%)

Table 84: Johnson & Johnson – Financial Overview, 2018 – 2022, $ Billion

Table 85: Merck & Co – Financial Overview, 2018 – 2022, $ Billion

Table 86: F. Hoffmann-La Roche Ltd – Financial Overview, 2018 – 2022, $ Billion

Table 87: Bristol-Myers Squibb – Financial Overview, 2018 – 2022, $ Billion

Table 88: GlaxoSmithKline plc – Financial Overview, 2018 – 2022, $ Billion

Table 89: Global Monoclonal Antibodies (MAbs) Market, Pipeline Analysis

Table 90: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), 2023 – 2028, By Country

Table 91: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By Source, 2023 – 2028

Table 92: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By Application, 2023 – 2028

Table 93: Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By End-Users, 2023 – 2028

Table 94: Monoclonal Antibodies (mAbs) Market Data Sources

List Of Figures

Figure 1: Global Monoclonal Antibodies (mAbs) Market Segmentation By Source

Figure 2: Global Monoclonal Antibodies (mAbs) Market Segmentation By Application

Figure 3: Global Monoclonal Antibodies (mAbs) Market Segmentation By End-Users

Figure 4: Global Monoclonal Antibodies (mAbs) Market, Historic, 2018 – 2023, $ Million

Figure 5: Global Monoclonal Antibodies (mAbs) Market, Forecast, 2023 – 2028, 2033F, $ Million

Figure 6: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 7: Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 8: Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 9: Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 10: Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 11: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 12: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 13: Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 14: China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 15: China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 16: China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 17: India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 18: India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 19: India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 20: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 21: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 22: Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 23: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 24: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 25: Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 26: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 27: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 28: Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 29: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 30: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 31: South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 32: Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 33: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 34: Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 35: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 36: UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 37: UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 38: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 39: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 40: Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 41: France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 42: France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 43: France Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 44: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 45: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 46: Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 47: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 48: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 49: Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 50: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 51: North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 52: North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 53: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 54: USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 55: USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 56: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 57: South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 58: South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 59: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 60: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 61: Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 62: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 63: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 64: Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 65: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 66: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 67: Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million

Figure 68: Global Monoclonal Antibodies (mAbs), Key Competitor Estimated Market Shares, 2022, Percentage (%)

Figure 69: Johnson & Johnson – Financial Overview, 2018 – 2022, $ Billion

Figure 70: Merck & Co – Financial Overview, 2018 – 2022, $ Billion

Figure 71: F. Hoffmann-La Roche Ltd – Financial Overview, 2018 – 2022, $ Billion

Figure 72: Bristol-Myers Squibb – Financial Overview, 2018 – 2022, $ Billion

Figure 73: GlaxoSmithKline plc – Financial Overview, 2018 – 2022, $ Billion

Figure 74: Geographic Regions Covered

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Oral Biologics & Biosimilar Drugs Global Market Report 2024 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Enzymes Global Market Report 2024 – By Product Type (Asparaginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products), By Application (Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications), By End User (Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Protein Inhibitors Global Market Report 2024 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Digestive Enzymes Global Market Report 2024 – By Enzyme Type (Carbohydrates, Protease, Lipase, Other Enzyme Types), By Origin (Animal, Fungi, Microbial, Plant), By Application (Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications), By Distribution Channel (Retail Stores, Online Stores) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033

Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033

Monoclonal Antibodies (mAbs)Market Definition

Monoclonal Antibodies (mAbs)Market Size

Monoclonal Antibodies (mAbs) Market Drivers

Monoclonal Antibodies (mAbs) Market Restraints

Monoclonal Antibodies (mAbs) Market Trends

Opportunities And Recommendations In The Monoclonal Antibodies (mAbs) Market

Monoclonal Antibodies (mAbs) Market Segmentation

Monoclonal Antibodies (Mabs) Market Competitive Landscape

Major Competitors are:

Other Competitors Include:

Table Of Contents

List Of Tables

List Of Figures

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Global Protein Purification And Isolation Market 2022 – Market Opportunities And Strategies

What Is The Pharmaceutical Processing Seals Market Overview In 2022?

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

Frequently Asked Questions